Uveitis Trial, Recruiting NCT05153057 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Uveitis
Back to Uveitis

Uveitis Trial, Recruiting

NCT05153057
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The condition affects both eyes.
  • There are at least three specific spots (called "birdshot lesions") below or to the inner side of the optic nerve in at least one eye.
  • There is only a small amount of inflammation in the front part of the eye (a low level, confirmed by an eye exam).
  • There is only a mild level of cloudiness or inflammation in the jelly-like fluid inside the eye (a low level, confirmed by an eye exam).

The following findings may also support eligibility (confirm with trial site):

  • A positive result for a specific genetic marker called HLA-A29.
  • Inflammation of the blood vessels in the retina.
  • Swelling in the central part of the retina (the macula).

Who may not be able to join:

  • There are deposits on the inner surface of the cornea (the clear front part of the eye), known as keratic precipitates.
  • There is scarring that causes the iris (the colored part of the eye) to stick to the lens inside the eye.
  • There is another condition present — such as an infection, a cancer-related condition, or a different inflammatory disease — that could cause similar-looking spots in the eye.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antoine BREZIN, PhD & MD, Université de Paris, Ophtalmopôle, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris.

Phone: +33 1 58412898

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
2 November 2004
Est. completion
31 December 2030

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Best Corrected Visual Acuity (BCVA); Visual field testing; Color vision; National Eye Institute 25-Item Visual Function Questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov